BEAM News and Press, Beam Therapeutics Inc. From 03/06/24

2024-03-06 16:16:26 ET More on Metagenomi, Inc. Stocks To Watch: Eyes On Broadcom, Target, Costco, Rivian And Small Caps Metagenomi Begins Genetic Treatment IPO Rollout Moderna-backed Metagenomi sees stock fall 31% after $94M IPO Metagenomi prices initial off...

2024-02-29 07:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in the following upcoming investor conferences: TD Cowen 44t...

Beam Therapeutics Inc. (NASDAQ: BEAM) is one of today's top gainers. The company's shares have moved 27.57% on the day to $45.67. Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company...

Patient Dosing and Enrollment Continue to Progress in Beacon Phase 1/2 Study of BEAM-101 in Severe Sickle Cell Disease; First Clinical Data Anticipated in Second Half of 2024 Phase 1 Trial Initiation for BEAM-302 in Alpha-1 Antitrypsin Deficiency on Track for First Half of 2024 Pending ...

First Solar Inc. (FSLR) is expected to report $3.19 for Q4 2023 VIZIO Holding Corp. Class A (VZIO) is expected to report $0.02 for Q4 2023 Henry Schein Inc. (HSIC) is expected to report $0.71 for Q4 2023 Republic Services Inc. (RSG) is expected to report $1.28 for Q4 2023 Forge Gl...

2024-02-08 04:32:36 ET Summary Beam Therapeutics has a diversified pipeline of cell and nanoparticle-based therapeutic candidates, but the lack of data does not justify its high valuation. The company has two main candidates in clinical trials, BEAM-101 and BEAM-201, targeting sic...

2024-02-07 17:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

CAMBRIDGE, Mass., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in a fireside chat at the Guggenheim Healthcare Talks 6 th Annua...

2024-01-29 18:21:00 ET Beam Therapeutics (NASDAQ: BEAM) stock thundered out of the gate this week, rising to close nearly 17% higher in price on Monday. Much of this was due to a recommendation upgrade from a prominent bank. By contrast, the S&P 500 only eked out a 0.8% gain...